All patients
subjects at risk
hydroxychloroquine in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.02; 49.67]
PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16]
0.99 [0.06 ; 15.95 ] COVID-PEP-Post exposure (Boulware), 2020, PATCH-cohort 3 PreP (Abella), 2020 2 0% 953 low not evaluable hospitalizationdetailed results COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.06; 15.77]
Rojas-Serrano, 2021 1.05 [0.02; 53.69]
1.00 [0.10 ; 9.70 ] COVID-PEP-Post exposure (Boulware), 2020, Rojas-Serrano, 2021 2 0% 948 low not evaluable symptomatic Covid-19detailed results Barnabas RV, 2020 1.27 [0.79; 2.04]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.65 [0.18; 2.33]
COVID PREP HCQ (2x week, Rajasingham), 2020 1.18 [0.40; 3.50]
COVID-PEP-Post exposure (Boulware), 2020 0.84 [0.55; 1.27]
HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15]
Rojas-Serrano, 2021 0.16 [0.02; 1.38]
0.89 [0.68 ; 1.17 ] Barnabas RV, 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, HERO-HCQ (Naggie), 2021, Rojas-Serrano, 2021 6 14% 5,113 low not evaluable asymptomatic COVID casedetailed results EPICOS (Polo), 2022 0.96 [0.49; 1.90]
0.96 [0.49 ; 1.90 ] EPICOS (Polo), 2022 1 0% 454 NA not evaluable infection (PCR positive symptomatic or not)detailed results Barnabas RV, 2020 1.10 [0.73; 1.66]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.73 [0.45; 1.19]
COVID PREP HCQ (2x week, Rajasingham), 2020 0.74 [0.45; 1.21]
COVID-PEP-Post exposure (Boulware), 2020 1.21 [0.49; 2.94]
EPICOS (Polo), 2022 0.87 [0.47; 1.62]
HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15]
PATCH-cohort 3 PreP (Abella), 2020 0.95 [0.23; 3.98]
Rojas-Serrano, 2021 0.16 [0.02; 1.38]
0.84 [0.69 ; 1.03 ] Barnabas RV, 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, EPICOS (Polo), 2022, HERO-HCQ (Naggie), 2021, PATCH-cohort 3 PreP (Abella), 2020, Rojas-Serrano, 2021 8 0% 5,692 low not evaluable serious adverse eventsdetailed results Barnabas RV, 2020 1.04 [0.15; 7.40]
PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16]
1.03 [0.18 ; 5.97 ] Barnabas RV, 2020, PATCH-cohort 3 PreP (Abella), 2020 2 0% 961 low not evaluable adverse eventsdetailed results Barnabas RV, 2020 1.58 [1.06; 2.37]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.59 [0.44; 0.79]
COVID PREP HCQ (2x week, Rajasingham), 2020 2.02 [1.52; 2.70]
COVID-PEP-Post exposure (Boulware), 2020 3.32 [2.33; 4.72]
Rojas-Serrano, 2021 1.64 [0.78; 3.42]
1.59 [0.83 ; 3.05 ] Barnabas RV, 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, Rojas-Serrano, 2021 5 94% 3,633 low not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:01 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 657,832
- roots T: 290
